Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study

• Published in: Neurology Vol. 88; no. 14; p. 1321
• Main Authors: Wissel, Jörg, Bensmail, Djamel, Ferreira, Joaquim J, Molteni, Franco, Satkunam, Lalith, Moraleda, Susana, Rekand, Tiina, McGuire, John, Scheschonka, Astrid, Flatau-Baqué, Birgit, Simon, Olivier, Rochford, Edward T J, Dressler, Dirk, Simpson, David M
• Format: Journal Article
• Language: English
• Published: United States 04.04.2017
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Botulinum Toxins, Type A - adverse effects; Botulinum Toxins, Type A - immunology; Dose-Response Relationship, Drug; Extremities; Female; Humans; Lung Diseases - etiology; Male; Middle Aged; Muscle Spasticity - complications; Muscle Spasticity - drug therapy; Neuromuscular Agents - adverse effects; Retrospective Studies; Vital Signs - drug effects; Young Adult
• ISSN: 1526-632X
• DOI: 10.1212/WNL.0000000000003789

To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity. In this prospective, single-arm, dose-titration study (NCT01603459), patients (18-80 years) with spasticity due to cerebral causes, who were clinically deemed to require total doses of 800 U incobotulinumtoxinA, received 3 consecutive injection cycles (ICs) with 400 U, 600 U, and 600-800 U incobotulinumtoxinA, respectively, each followed by 12-16 weeks' observation. Outcomes included adverse events (AEs), antibody testing, Resistance to Passive Movement Scale (REPAS; based on the Ashworth Scale), and Goal Attainment Scale. In total, 155 patients were enrolled. IncobotulinumtoxinA dose escalation did not lead to an increased incidence of treatment-related AEs (IC1: 4.5%; IC2: 5.3%; IC3: 2.9%). No treatment-related serious AEs occurred. The most frequent AEs overall were falls (7.7%), nasopharyngitis, arthralgia, and diarrhea (6.5% each). Five patients (3.2%) discontinued due to AEs. No patient developed secondary nonresponse due to neutralizing antibodies. Mean (SD) REPAS score improvements from each injection to 4 weeks postinjection increased throughout the study (IC1: -4.6 [3.9]; IC2: -5.9 [4.2]; IC3: -7.1 [4.8]; < 0.0001 for all). The proportion of patients achieving ≥3 (of 4) treatment goals also increased (IC1: 25.2%; IC2: 50.7%; IC3: 68.6%). Escalating incobotulinumtoxinA doses (400 U up to 800 U) did not compromise safety or tolerability, enabled treatment in a greater number of muscles/spasticity patterns, and was associated with increased treatment efficacy, improved muscle tone, and goal attainment. NCT01603459. This study provides Class IV evidence that, for patients with limb spasticity, escalating incobotulinumtoxinA doses (400 U up to 800 U) increases treatment efficacy without compromising safety or tolerability.